Zacks Investment Research
26 Aug 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Medtronic is expected to report first-quarter fiscal 2027 EPS of $1.39 and revenue of $9.47 billion on September 1, representing YoY growth of 10.3% and 10.4% respectively. — Double-digit growth expectations for a large-cap medical device company typically support a positive price trajectory if met or exceeded.
+0.30The Cardiac Ablation Solutions segment, specifically the pulsed field ablation portfolio, is identified as a key growth driver following a 145% growth rate in the previous quarter. — Strong momentum in a specific high-growth product line provides a fundamental catalyst for revenue beats.
+0.20Medtronic has beaten earnings estimates in each of the past four quarters with an average surprise of 2.3%. — A consistent history of beats increases investor confidence in the company's guidance and reporting accuracy.
+0.10Continue reading
6 related stories
Search tags
The company currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%, suggesting no current upward revision momentum in estimates. — The lack of positive estimate revisions (ESP) suggests the market has already priced in the expected results, limiting upside surprise.
-0.10Which stocks this story touches
The company has a solid earnings surprise history and positive growth drivers in its Cardiac Ablation Solutions segment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
4h ago
